DUBLIN, August 16, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Radiation Therapy in Oncology Drug Pipeline Update" drug pipelines to their offering.
This drug pipeline update is structured around radiolabeled drugs, radiosensitizers and radioprotective compounds.
There are today 322 companies plus partners developing 313 radiation therapy drugs in 692 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 150 drugs.
Radiation Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 179 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 174 out of the 175 studied drug targets so far have been recorded with somatic mutations.
Pipeline Breakdown According to Number of Drugs
- Marketed# 93
- Registered# 1
- Pre-registration# 5
- Phase III# 47
- Phase II# 103
- Phase I# 62
- Preclinical# 73
- No Data# 5
- Suspended# 7
- Ceased# 150
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/qj66n5/radiation_therapy
Related Topics: Oncology Drugs , Radiography
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets